APP Pharmaceuticals Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding Inc., (APCVZ) announced that it has received U.S. Food and Drug Administration or FDA approval to market Sumatriptan Succinate Injection, USP, in two dosage strengths.
APP said it will package Sumatriptan Succinate Injection in pre-filled syringes of 4 mg (base) /0.5 mL and 6 mg (base) / 0.5 mL. .
APP's Sumatriptan Succinate Injection is AP-rated, bar-coded and latex-free. The company said that Sumatriptan Succinate Injection is a vascular headache suppressant indicated for the acute treatment of migraine attacks with or without aura and the acute treatment of cluster headache episodes.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.